KYMR Stock Analysis: Buy, Sell, or Hold?
KYMR - Kymera Therapeutics, Inc. Common Stock
$117.39
2.97 (2.60%)
â˛
5d:
+9.18%
30d:
+2.98%
90d:
+38.92%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When KYMR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: KYMR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: KYMR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: KYMR is currently trading at $117.39, which is considered fair relative to its 30-day fair value range of $105.65 to $115.30.
Technical Outlook: Technically, KYMR is in a strong uptrend. The price is approaching resistance at $118.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KYMR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $130.91 (+11.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KYMR is in a strong uptrend. The price is approaching resistance at $118.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KYMR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $130.91 (+11.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$105.65 -
$115.30
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
Protect Your Profits
Holding KYMR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($130.91)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$105.65 -
$115.30
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$99.52
Resistance Level
$118.04
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.67
Wall Street Target
$130.91
(+11.5%)
Revenue Growth (YoY)
466.4%
Profit Margin
-285.3%
Share & Embed Analysis
Last updated: August 16, 2026 2:49 AM ET
Data refreshes hourly during market hours. Next update: 3:49 AM
Data refreshes hourly during market hours. Next update: 3:49 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYMR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Bruce Booth
SELL
5900 shares
2026-04-22
Jeremy G Chadwick
SELL
300 shares
2026-04-22
Bruce Booth
SELL
100 shares
2026-04-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 41 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 49 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$140 | 67 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 55 HOLD |
Advanced KYMR Option Strategies
Professional options setups generated by AI based on today's KYMR price and gamma walls.
